Laboratorio Reig Jofre Beheer

Mr. Ignasi Biosca Reig has been Chief Executive Officer of Laboratorio Reig Jofre, S.A. since January 13, 2015. Mr. Reig served as Chief Executive Officer of Reig Jofre since 2006. He served as Consultant...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ignasi Reig	CEO & Executive Director	9.9yrs	€445.00k	0.010% € 22.1k
Maria Luisa Plaza	Independent Director	9.9yrs	€40.00k	geen gegevens
Isabel López	Proprietary Chairman of the Board	9.9yrs	geen gegevens	geen gegevens
Alejandro Reig	Vice President of the Board	9.9yrs	€40.00k	geen gegevens
Ramon i de Barbara	Independent Director	9.9yrs	€36.00k	geen gegevens
Ramiro del Valle	Independent Director	9.9yrs	€40.00k	geen gegevens
Emilio Martinez	Independent Director	9.9yrs	€40.00k	geen gegevens
Alvaro Zubiria	Proprietary Director	no data	geen gegevens	0.030% € 66.4k

9.9yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van RJF wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.9 jaar).

Laboratorio Reig Jofre Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Laboratorio Reig Jofre, S.A., Annual General Meeting, Apr 10, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Third quarter 2024 earnings released

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings released

Calculating The Fair Value Of Laboratorio Reig Jofre, S.A. (BME:RJF)

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: €0.041 (vs €0.036 in 1Q 2023)

Laboratorio Reig Jofre, S.A. to Report Q3, 2024 Results on Oct 31, 2024

Price target decreased by 13% to €4.10

Consensus EPS estimates fall by 32%

Laboratorio Reig Jofre, S.A., Annual General Meeting, Apr 10, 2024

Full year 2023 earnings released

Price target increased by 9.3% to €4.70

First half 2023 earnings released: EPS: €0.07 (vs €0.047 in 1H 2022)

Consensus EPS estimates fall by 12%, revenue upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That Laboratorio Reig Jofre (BME:RJF) Is Using Debt Extensively

Price target decreased to €3.80

Insufficient new directors

First half 2022 earnings released

Consensus EPS estimates increase by 11%

Laboratorio Reig Jofre, S.A. to Report Q3, 2022 Results on Oct 28, 2022

Price target decreased to €4.10

Insufficient new directors

This Analyst Just Downgraded Their Laboratorio Reig Jofre, S.A. (BME:RJF) EPS Forecasts

We Think Laboratorio Reig Jofre (BME:RJF) Is Taking Some Risk With Its Debt

Price target decreased to €4.10

Full year 2021 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Second quarter 2021 earnings released

Laboratorio Reig Jofre, S.A. (BME:RJF) acquired remaining 49% stake in Reig Jofre UK Ltd from FIEX managed by Compañía Española de Financiación del Desarrollo, COFIDES, S.A, S.M.E.

Investor sentiment improved over the past week

Laboratorio Reig Jofre (BME:RJF) Seems To Use Debt Quite Sensibly

First quarter 2021 earnings released: EPS €0.048

Laboratorio Reig Jofre, S.A. to Report Fiscal Year 2020 Final Results on Mar 05, 2021

The Laboratorio Reig Jofre (BME:RJF) Share Price Has Gained 146%, So Why Not Pay It Some Attention?

Laboratorio Reig Jofre, S.A. to Report Q2, 2021 Results on Jul 29, 2021

Investor sentiment improved over the past week

New 90-day high: €4.90

Laboratorio Reig Jofre, S.A. announced that it has received €24 million in funding

New 90-day high: €4.76

Is Laboratorio Reig Jofre (BME:RJF) Using Too Much Debt?

Investor sentiment improved over the past week

Laboratorio Reig Jofre (BME:RJF) Shareholders Booked A 47% Gain In The Last Year

New 90-day low: €3.82

First half earnings released

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur